AU776288B2 - Methods and adjuvants for stimulating mucosal immunity - Google Patents

Methods and adjuvants for stimulating mucosal immunity Download PDF

Info

Publication number
AU776288B2
AU776288B2 AU62493/99A AU6249399A AU776288B2 AU 776288 B2 AU776288 B2 AU 776288B2 AU 62493/99 A AU62493/99 A AU 62493/99A AU 6249399 A AU6249399 A AU 6249399A AU 776288 B2 AU776288 B2 AU 776288B2
Authority
AU
Australia
Prior art keywords
iss
odn
host
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU62493/99A
Other languages
English (en)
Other versions
AU6249399A (en
Inventor
Dennis A. Carson
Anthony A. Horner
Eyal Raz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU6249399A publication Critical patent/AU6249399A/en
Application granted granted Critical
Publication of AU776288B2 publication Critical patent/AU776288B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU62493/99A 1998-10-05 1999-09-15 Methods and adjuvants for stimulating mucosal immunity Expired - Fee Related AU776288B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16703998A 1998-10-05 1998-10-05
US09/167039 1998-10-05
PCT/US1999/021203 WO2000020039A1 (fr) 1998-10-05 1999-09-15 Procedes et adjuvants stimulant l'immunite des muqueuses

Publications (2)

Publication Number Publication Date
AU6249399A AU6249399A (en) 2000-04-26
AU776288B2 true AU776288B2 (en) 2004-09-02

Family

ID=22605695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62493/99A Expired - Fee Related AU776288B2 (en) 1998-10-05 1999-09-15 Methods and adjuvants for stimulating mucosal immunity

Country Status (5)

Country Link
EP (1) EP1119375A4 (fr)
JP (1) JP2002526425A (fr)
AU (1) AU776288B2 (fr)
CA (1) CA2346452A1 (fr)
WO (1) WO2000020039A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1176966B1 (fr) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
ATE378348T1 (de) 2000-01-14 2007-11-15 Us Health Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
AU2001249609A1 (en) 2000-03-28 2001-10-08 Department Of Veterans Affairs Methods for increasing a cytotoxic T lymphocyte response in vivo
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
WO2004098491A2 (fr) 2002-11-01 2004-11-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
WO2004053104A2 (fr) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. Acides nucleiques 5'cpg et leurs methodes d'utilisation
CN1798563A (zh) 2003-05-15 2006-07-05 独立行政法人科学技术振兴机构 免疫刺激剂
JP4817625B2 (ja) * 2003-08-11 2011-11-16 一般財団法人阪大微生物病研究会 粘膜免疫誘導アジュバントを含む新規ワクチン
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
US8211442B2 (en) 2005-08-05 2012-07-03 The University Of Tokushima Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
WO2021176434A1 (fr) * 2020-03-01 2021-09-10 Valneva Austria Gmbh Vaccin contre le virus sras-cov-2 à adjuvant cpg

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016247A1 (fr) * 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU9302398A (en) * 1997-09-05 1999-03-22 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167377B2 (fr) * 1994-07-15 2012-08-08 University of Iowa Research Foundation Oliogonucléotides immunomodulateurs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016247A1 (fr) * 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
AU9302398A (en) * 1997-09-05 1999-03-22 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation

Also Published As

Publication number Publication date
EP1119375A4 (fr) 2005-02-02
JP2002526425A (ja) 2002-08-20
WO2000020039A1 (fr) 2000-04-13
WO2000020039A9 (fr) 2000-09-21
CA2346452A1 (fr) 2000-04-13
EP1119375A1 (fr) 2001-08-01
AU6249399A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
AU776288B2 (en) Methods and adjuvants for stimulating mucosal immunity
US7208478B2 (en) Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU757175B2 (en) Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
CA2412026A1 (fr) Molecules hybrides arn/adn immunostimulatrices
AU2003241251B2 (en) Biofunctional CpG or oligo-/polynucleotide and toxin or enterotoxin containing composition
Linghua et al. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets
Babiuk et al. Biphasic Lipid Vesicles (Biphasix™) Enhance the Adjuvanticity of CpG Oligonucleotides Following Systemic and Mucosal Administration
Horner et al. Mucosal adjuvanticity of immunostimulatory DNA sequences
AU768178B2 (en) Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
Horner et al. Immunostimulatory-sequence DNA is an effective mucosal adjuvant
AU2003203948B2 (en) Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
US20110111016A1 (en) Non-dna base-containing polynucleotide compositions and their use for the modulation of immune responses
Horner Immunostimulatory DNA Sequence Based Mucosal Vaccines